ストックスクリーナーアプリを入手
0.8544
0.65%
-0.0056
Actinium Pharmaceuticals Inc (ATNM) 最新ニュース
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM)Join by May 27, 2025Contact Levi & Korsinsky - The National Law Review
Actinium Pharmaceuticals Inc (ATNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Did You Lose Money on Actinium Pharmaceuticals, Inc. (ATNM)? Levi - The National Law Review
ATNM|Actinium Pharmaceuticals Inc|Price:0.860|Chg%:-0.024 - TradingKey
TradingKey - TradingKey
Actinium Pharmaceuticals Inc|Price:0.860|Chg%:-0.024 - TradingKey
Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
Actinium Pharmaceuticals (ATNM) Life Sciences Investor Forum Summary - Quartr
Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support ZoneVWAP Breakout - dars.gov.et
Actinium Pharmaceuticals (ATNM) Gains 2.77% as Stock Tests Key Resistance Near $0.97Jelly Roll Trade - dars.gov.et
Actinium Pharmaceuticals (ATNM) Investor presentation Summary - Quartr
Actinium Pharmaceuticals (ATNM) Proxy Filing Summary - Quartr
ATNM Should I Buy - Intellectia AI
Actinium Pharmaceuticals (ATNM) Q4 2025 earnings summary - Quartr
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - AOL.com
Actinium Company Profile & Introduction - Moomoo
ATNMActinium Pharmaceuticals Inc Earnings - Finviz
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - The National Law Review
ATNM Stockholders Have Opportunity to Lead Actinium Pharmaceutica - The National Law Review
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceut - The National Law Review
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Joi - The National Law Review
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceutical - The National Law Review
Enterprise value to revenue forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Price to sales forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Price to earnings forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Price to book forward of Actinium Pharmaceuticals, Inc. (Delaware) – AMEX:ATNM - TradingView
Actinium Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ATNM) - TradingView
ATNM Forecast — Price Target — Prediction for 2027 - TradingView
Actinium Pharmaceuticals Inc (ATNM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrowed Loss Surpasses Expectations Amid Pipeline ProgressTangible Book Value - dars.gov.et
Actinium Submits NYSE Compliance Plan to Restore Listing - The Globe and Mail
Actinium Pharmaceuticals Inc (ATNM) Institutional Confidence - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actinium Pharmaceuticals Submits NYSE American Compliance Plan After Equity Deficiency Notice - Minichart
Actinium (NYSE: ATNM) details plan to regain NYSE American listing - Stock Titan
Actinium Pharmaceuticals Inc (ATNM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Actinium Pharmaceuticals Inc - TradingKey
Actinium Pharmaceuticals (ATNM) Q1 2026 Earnings: Narrower-than-expected loss surprises positively; shares slipManagement Tone Analysis - DonanımHaber
Actinium Pharmaceuticals presents expanded ATNM-400 results in NSCLC and prostate cancer - Traders Union
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC - BioWorld News
Actinium presents preclinical data on ATNM-400 for lung cancer - Investing.com UK
Actinium Pharmaceuticals (ATNM) Reveals Promising Preclinical Data for NSCLC Treatment - GuruFocus
Actinium presents preclinical data on ATNM-400 for lung cancer By Investing.com - Investing.com Canada
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PR Newswire
Actinium Pharmaceuticals (ATNM) Appoints New Chief Medical Officer - GuruFocus
Actinium Pharmaceuticals (ATNM) Unveils Key Radiochemistry Findi - GuruFocus
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PR Newswire
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PR Newswire
Actinium Pharmaceuticals appoints Dr. Steffen H... - Pluang
Actinium Pharmaceuticals Presents ATNM-400 Program Updates at SNMMI 2026 and Addresses NYSE American Listing Compliance Notice - Minichart
Actinium Pharmaceuticals Advances with Canadian Patent Allowances for ATNM - GuruFocus
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):